Analyst Ratings For Arbutus Biopharma (NASDAQ:ABUS)
Today, Chardan Capital initiated coverage on Arbutus Biopharma (NASDAQ:ABUS) with a Buy with a price target of $8.25.
Some recent analyst ratings include
- 3/19/2018-Chardan Capital initiated coverage with a Buy rating.
- 3/19/2018-Wedbush was Downgraded by analysts at Wedbush from a “Outperform ” rating to a ” Neutral” rating. They now have a $6.00 price target on the stock.
- 1/5/2018-B. Riley initiated coverage with a Buy rating.
- 11/7/2017-Leerink Swann Reiterated Rating of Market Perform.
- 10/4/2017-JMP Securities Reiterated Rating of Outperform.
- 6/2/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 1/9/2017-Bloom Burton Upgrade from a “Accumulate ” rating to a ” Buy” rating.
Recent Insider Trading Activity For Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma (NASDAQ:ABUS) has insider ownership of 6.90% and institutional ownership of 62.14%.
- On 10/3/2017 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.00 per share and the total transaction amounting to $80,000.00.
- On 8/15/2017 Michael J Sofia, Insider, sold 30,000 with an average share price of $3.70 per share and the total transaction amounting to $111,000.00.
- On 8/24/2015 Richard C Henriques Jr, Director, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00.
Recent Trading Activity for Arbutus Biopharma (NASDAQ:ABUS)
Shares of Arbutus Biopharma closed the previous trading session at with 5.050000190734863 shares trading hands.
